Abstract
We retrospectively analyzed hematologic parameters in 22 patients with advanced, nonsquamous, NSCLC undergoing VEGF inhibition on a phase II clinical trial of bevacizumab, carboplatin, and gemcitabine. We also examined TTP in relation to hemoglobin changes. Median hemoglobin increased significantly from a 12.9 g/dL pretreatment to 13.8 g/dL (p =.01) after the second cycle of maintenance bevacizumab until the first off cycle measurement. There was no difference in TTP in patients who achieved a rise in hemoglobin compared with patients who did not (median 238 days vs. 268 days, p =.38.) Maintenance bevacizumab is associated with increased hemoglobin in advanced, nonsquamous, NSCLC patients.
Publication types
-
Clinical Trial, Phase II
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Angiogenesis Inhibitors / therapeutic use*
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Bevacizumab
-
Carcinoma, Non-Small-Cell Lung / blood
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / mortality
-
Erythropoietin / blood
-
Female
-
Hemoglobins / analysis*
-
Humans
-
Lung Neoplasms / blood
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / mortality
-
Male
-
Middle Aged
-
Retrospective Studies
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors*
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal, Humanized
-
Hemoglobins
-
Vascular Endothelial Growth Factor A
-
Erythropoietin
-
Bevacizumab